Celgene Corp

Most Recent

  • uploads///revenue EE
    Earnings Report

    How Vertex’s Revenue and Earnings Surprised in 2Q16

    Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

    By Jillian Dabney
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Biotech Stocks Have Witnessed a Tremendous Growth in Earnings
    Macroeconomic Analysis

    Why Do Biotech Stocks Look Attractive?

    Today, biotech is one of the hottest investment areas. It’s driven by the demand for effective treatments and new cures. Stocks had strong growth in recent years.

    By BlackRock
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///pills _
    Company & Industry Overviews

    AbbVie Has Raised Its EPS Guidance for 2018

    On its second-quarter earnings conference call, AbbVie (ABBV) raised its 2018 EPS guidance by $0.10.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Does the Future Hold for Seattle Genetics?

    Seattle Genetics has surpassed all estimates for earnings per share in the past.

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Celgene in 2017

    Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

    By Daniel Collins
  • uploads///ANR
    Company & Industry Overviews

    Here Are the Latest Analyst Recommendations for Biogen

    The consensus 12-month target price for Biogen is $342.7, an ~11.4% return potential.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    XLV Was Trading Higher after Paying Dividends

    The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///CELG Revlimid
    Company & Industry Overviews

    Analyzing the Performance of Celgene’s Hematology Portfolio

    Celgene’s total worldwide sales of the hematology/oncology category increased from $2.7 billion in 1Q17 to $3.1 billion in 1Q18.

    By Kenneth Smith
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///CELG Otezla
    Company & Industry Overviews

    Performance of Celgene’s Inflammation and Immunology Products

    Total worldwide sales of Celgene’s other products—including Idhifa, Thalomid, and Istodax—increased from $226.0 million in 1Q17 to $229.0 million in 1Q18.

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Celgene Projects for Its Fiscal 2018 Revenue

    Wall Street analysts expect Celgene to report revenues of $15.22 billion in fiscal 2018.

    By Margaret Patrick
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Venclexta May Prove a Novel Chemotherapy-Free Treatment Option

    In 2017, AbbVie (ABBV) and Roche Holdings’ (RHHBY) Venclexta reported positive data from its Phase 3 trial, MURANO.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Imbruvica Continues to Expand across Indications and Lines of Therapy

    Imbruvica managed to earn revenues of about $381 million in 1Q16, which comprised of $325 million from the US market and $56 million from foreign markets.

    By Margaret Patrick
  • uploads///microbiology _
    Company & Industry Overviews

    Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals

    Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal.

    By Sarah Collins
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///dna _
    Healthcare

    Amgen Stock Rises over 2% on Drug Approvals

    Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.

    By Mike Benson
  • uploads///Chart  CELG
    Company & Industry Overviews

    Celgene Stock Performance in 1Q18

    Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///reent wins
    Company & Industry Overviews

    Inside Bristol’s Key to Success: Multiple Labels for Opdivo

    Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///ousa chea  unsplash
    Healthcare

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

    By Mike Benson
  • uploads///Stelara
    Company & Industry Overviews

    JNJ’s Stelara Witnessed High Growth in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018

    Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.

    By Mike Benson
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How Celgene Reacted to Positive Clinical Trials on October 26, 2015

    Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.

    By Peter Neil
  • uploads///AdobeStock_
    Fund Managers

    What Were the Top Holdings of Citadel Advisors in Q3?

    In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.

    By Rabindra Samanta
  • uploads///Graph
    Company & Industry Overviews

    New Indications May Be Big Opportunity for AbbVie’s Imbruvica

    On September 26, 2016, AbbVie (ABBV) said it has submitted an application to the FDA for Imbruvica as a treatment for previously treated patients with marginal zone lymphoma.

    By Margaret Patrick
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene to File NDA for Ozanimod as Multiple Sclerosis Therapy

    If ozanimod captures a significant share in the evolving multiple sclerosis market, it may have a positive impact on Celgene stock.

    By Margaret Patrick
  • uploads///Part  Graph
    Earnings Report

    Horizon Pharma Appears to Be on an Acquisition Spree

    Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.

    By Peter Neil
  • uploads///HBbuysell
    Consumer

    Overview: Highbridge Capital Management’s 2Q14 positions

    Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///hands _
    Healthcare

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.

    By Mike Benson
  • uploads///world _
    Healthcare

    Pharma’s Latest: Mergers and Acquisitions in 1Q18

    Let’s take a look at the mergers and acquisitions that took place in the US pharmaceutical sector in 1Q18.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amgen Expects Competitive Pressures for Its Mature Brands in 2016

    Following the launch of Novartis’s biosimilar Zarxio in September 2015, Amgen’s Neupogen, a short-acting filgrastim, has witnessed a gradual fall in its revenue.

    By Margaret Patrick
  • uploads///AdobeStock_
    Consumer

    The George Soros Fund Shares 13F Analysis

    On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.

    By Rabindra Samanta
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///PCYC ABBV b cells
    Miscellaneous

    Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger?

    In preparation for the Pharmacyclics–AbbVie merger, the companies will have to file under the Hart-Scott-Rodino Antitrust Improvements Act.

    By Brent Nyitray, CFA, MBA
  • uploads///II Pipeline
    Company & Industry Overviews

    What’s in Celgene’s Immunology and Inflammation Clinical Pipeline?

    Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Otezla Expected to Post Strong Revenue in 2017

    According to unaudited financial results for Celgene (CELG) on January 9, 2017, Otezla sales for 2016 were about $1.0 billion. That’s a YoY rise of about 116.0%.

    By Margaret Patrick
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Xeljanz ER Is Driving Growth for Pfizer This Year

    On July 28, 2016, Pfizer announced positive results from the Phase 3 trial testing efficacy of Xeljanz as therapy for patients suffering with moderate to severely active ulcerative colitis (or UC).

    By Margaret Patrick
  • uploads///BioMarin Financial projections
    Earnings Report

    BioMarin: How Much Revenue Growth in 2Q16?

    According to analyst estimates, BioMarin should earn $278.4 million and $273.5 million in 2Q16 and 3Q16, respectively. That’s a yearly sales growth of 11.1% and 30.9%, respectively.

    By Jillian Dabney
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Which Biotechnology Companies Could Benefit from Brexit?

    The weak pound is expected to negatively affect biotechnology companies with a high revenue exposure to the United Kingdom.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Pomalyst
    Company & Industry Overviews

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth

    On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    How Did AbbVie Perform in 1Q16?

    AbbVie posted its 1Q16 earnings on April 28, 2016. The company registered diluted EPS (earnings per share) attributable to common shareholders of $1.15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Celgene’s Operating Expenses in 3Q15

    In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside AbbVie’s Analyst Recommendations in 2016

    Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene Estimates Robust Revenue in 2017

    In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Have to Say about Bristol-Myers Squibb?

    Analyst recommendations for BMY Bristol-Myers Squibb (BMY) is a leading immuno-oncology company. According to a Bloomberg consensus of 26 brokerage firms recorded on October 5, 2016, 42.3% of analysts recommended Bristol as a “buy” and 50% of analysts issued a “hold” rating for the company. Around 7.7% of analysts rated the stock as a “sell.” The […]

    By Jillian Dabney
  • uploads///Part  Graph
    Earnings Report

    Horizon Pharma’s Specialty Business Unit in 2Q15

    As per a company press release, Horizon Pharma’s (HZNP) specialty business unit consists of two products: RAYOS and Lodotra.

    By Peter Neil
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Peak Sales of $7 Billion for Imbruvica

    AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Venclexta for Chronic Lymphocytic Leukemia

    AbbVie (ABBV) and Roche Holdings (RHHBY) have strategized to position Venclexta as a foundation therapy in the chronic lymphocytic leukemia (or CLL) indication.

    By Margaret Patrick
  • uploads///AdobeStock_
    Energy & Utilities

    Analyzing Tudor Investment’s Top Holdings

    Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    Renaissance Technologies: Top Investments

    Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Company & Industry Overviews

    Amgen and Celgene’s Otezla Deal: Key Highlights

    On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

    By Margaret Patrick
  • uploads///entrepreneur _
    Company & Industry Overviews

    How PFE’s and BMY’s EPS Trends Compare

    In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.

    By Margaret Patrick
  • uploads///sapling _
    Company & Industry Overviews

    Bristol-Myers Squibb’s Oncology Treatment Growth Drivers

    Revenue for Bristol-Myers Squibb’s (BMY) Opdivo has grown by a double-digit percentage YoY (year-over-year) since 2016.

    By Margaret Patrick
  • uploads///feedback _
    Company & Industry Overviews

    What Analysts Recommend for Bristol-Myers Squibb and Celgene

    The consensus recommendation for Bristol-Myers Squibb is a “buy,” while the consensus for Celgene is a “hold.”

    By Margaret Patrick
  • uploads///achievement _
    Company & Industry Overviews

    What’s the Latest on the BMY-Celgene Deal?

    Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt

    AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?

    On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Is AbbVie or Celgene Expected to Report Faster Revenue Growth?

    On January 3, Bristol-Myers Squibb (BMY) issued a press release announcing that it had entered into a definitive agreement to acquire Celgene.

    By Margaret Patrick
  • uploads///bacteria _
    Company & Industry Overviews

    What Analysts Recommend for AbbVie and Celgene This Month

    On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Revlimid and Pomalyst Continued to Be Growth Drivers for Celgene

    On January 7, 2019, Celgene (CELG) issued a press release announcing its strategy to maximize the commercial potential of its major revenue-earning hemato-oncology assets.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Can Celgene’s Revenues Impress the Market in Q4 2018?

    On January 7, Celgene (CELG) issued a press release announcing that the company earned revenues of $15.2 billion for fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?

    Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

    By Margaret Patrick
  • uploads///Part
    Consumer

    Ray Dalio’s Advice Is to ‘Go Counter-Cyclical’

    Ray Dalio thinks of the markets in the context of the economic machine, wherein cycles repeat themselves.

    By Anuradha Garg
  • uploads///Graph
    Company & Industry Overviews

    Key Growth Drivers for Bristol-Myers Squibb Going Forward

    Bristol-Myers Squibb (BMY) will target four major therapeutic areas after completing the acquisition of Celgene (CELG).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BMY and Celgene to Form a Leading Global BioPharma Company

    According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years

    According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What to Expect from Bristol-Myers Squibb’s Earnings in 2019

    Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3.05 to $3.15 and non-GAAP EPS in the range of $3.80 to $3.90 for fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Bristol-Myers Squibb’s Revenues Look Heading into 2019

    In its third-quarter earnings conference call, Bristol-Myers Squibb (BMY) has forecasted high-single-digit YoY revenue growth for fiscal 2018.

    By Margaret Patrick
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Bristol-Myers Squibb to Acquire Celgene

    Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    Let’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance

    Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    A Look at Abraxane’s Revenue Growth Trajectory in 2018

    In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.